CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS rates ...
Patients with undetectable CD20 expression had worse outcomes with bispecific antibodies for DLBCL, highlighting the importance of target antigen expression in predicting treatment success. Real-world ...
CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells. CD20 × ...
CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders. Its ...
MILAN, June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting ...
A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.
Lunsumio VELO targets CD20 on lymphoma cells and lymphocytes, enhancing immune response against cancer cells. The subcutaneous version offers a one-minute administration, reducing clinic time and side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results